128 related articles for article (PubMed ID: 35729784)
1. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.
Priestley ES; Banville J; Deon D; Dubé L; Gagnon M; Guy J; Lapointe P; Lavallée JF; Martel A; Plamondon S; Rémillard R; Ruediger E; Tremblay F; Posy SL; Guarino VR; Richter JM; Li J; Gupta A; Vetrichelvan M; Balapragalathan TJ; Mathur A; Hua J; Callejo M; Guay J; Sum CS; Cvijic ME; Watson C; Wong P; Yang J; Bouvier M; Gordon DA; Wexler RR; Marinier A
J Med Chem; 2022 Jul; 65(13):8843-8854. PubMed ID: 35729784
[TBL] [Abstract][Full Text] [Related]
2. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.
Wilson SJ; Ismat FA; Wang Z; Cerra M; Narayan H; Raftis J; Gray TJ; Connell S; Garonzik S; Ma X; Yang J; Newby DE
Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):448-456. PubMed ID: 29269513
[TBL] [Abstract][Full Text] [Related]
3. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
Wong PC; Seiffert D; Bird JE; Watson CA; Bostwick JS; Giancarli M; Allegretto N; Hua J; Harden D; Guay J; Callejo M; Miller MM; Lawrence RM; Banville J; Guy J; Maxwell BD; Priestley ES; Marinier A; Wexler RR; Bouvier M; Gordon DA; Schumacher WA; Yang J
Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053157
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of BMS-986120 and its deuterated derivatives as PAR4 antagonists.
Chen P; Ren S; Song H; Chen C; Chen F; Xu Q; Kong Y; Sun H
Bioorg Med Chem; 2019 Jan; 27(1):116-124. PubMed ID: 30503410
[TBL] [Abstract][Full Text] [Related]
5. New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans.
Merali S; Wang Z; Frost C; Callejo M; Hedrick M; Hui L; Meadows Shropshire S; Xu K; Bouvier M; DeSouza MM; Yang J
Platelets; 2022 Oct; 33(7):969-978. PubMed ID: 35758258
[TBL] [Abstract][Full Text] [Related]
6. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
7. An optimized agonist peptide of protease-activated receptor 4 and its use in a validated platelet-aggregation assay.
Yang J; Mapelli C; Wang Z; Sum CS; Hua J; Lawrence RM; Ni Y; Seiffert DA
Platelets; 2022 Oct; 33(7):979-986. PubMed ID: 35343875
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 7, 4'-dimethoxy-3-hydroxyflavone as a protease-activated receptor 4 antagonist with antithrombotic activity and less bleeding tendency in mice.
Lin YT; Li Y; Hsu HC; Tsai JY; Lee JH; Tai CJ; Wu MJ; Wu CC
Biochem Pharmacol; 2022 Aug; 202():115152. PubMed ID: 35752281
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.
Miller MM; Banville J; Friends TJ; Gagnon M; Hangeland JJ; Lavallée JF; Martel A; O'Grady H; Rémillard R; Ruediger E; Tremblay F; Posy SL; Allegretto NJ; Guarino VR; Harden DG; Harper TW; Hartl K; Josephs J; Malmstrom S; Watson C; Yang Y; Zhang G; Wong P; Yang J; Bouvier M; Seiffert DA; Wexler RR; Lawrence RM; Priestley ES; Marinier A
J Med Chem; 2019 Aug; 62(16):7400-7416. PubMed ID: 31246024
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
Meah MN; Raftis J; Wilson SJ; Perera V; Garonzik SM; Murthy B; Everlof JG; Aronson R; Luettgen J; Newby DE
Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2678-2685. PubMed ID: 32907366
[TBL] [Abstract][Full Text] [Related]
11. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021).
Yu X; Li S; Zhu X; Kong Y
Expert Opin Ther Pat; 2022 Feb; 32(2):153-170. PubMed ID: 35081321
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold.
Liu S; Yuan D; Li S; Xie R; Kong Y; Zhu X
Eur J Med Chem; 2021 Dec; 225():113764. PubMed ID: 34391031
[TBL] [Abstract][Full Text] [Related]
14. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.
Kahn ML; Nakanishi-Matsui M; Shapiro MJ; Ishihara H; Coughlin SR
J Clin Invest; 1999 Mar; 103(6):879-87. PubMed ID: 10079109
[TBL] [Abstract][Full Text] [Related]
15. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
[TBL] [Abstract][Full Text] [Related]
16. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
17. Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
Liu S; Li S; Yuan D; Wang E; Xie R; Zhang W; Kong Y; Zhu X
Eur J Med Chem; 2021 Jan; 209():112893. PubMed ID: 33049608
[TBL] [Abstract][Full Text] [Related]
18. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
Lee H; Sturgeon SA; Jackson SP; Hamilton JR
Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047
[TBL] [Abstract][Full Text] [Related]
19. Challenges and promises of developing thrombin receptor antagonists.
Yang J; Xu K; Seiffert D
Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):162-70. PubMed ID: 20874673
[TBL] [Abstract][Full Text] [Related]
20. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
Holinstat M; Voss B; Bilodeau ML; McLaughlin JN; Cleator J; Hamm HE
J Biol Chem; 2006 Sep; 281(36):26665-74. PubMed ID: 16837456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
